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Abstract
Background: A new serum marker of inflammation copeptin (CPP) a stable C-terminal pro-vasopressin was assessed
along with conventional markers such as C-reactive protein (CRP), procalcitonin (PCT) and IL-6 to discriminate between
lower and upper bacterial urinary tract infections (UTI).
Methods: Study population comprised 45 patients including 13 with lower UTI (L-UTI) and 32 with upper UTI (U-UTI)
and 24 healthy controls. Serum markers, blood cultures and urine cultures were assessed before commencing
antibiotic treatment and repeated 24, 48 h and 7 days thereafter. Receiver operating curves (ROC) were plotted
to assess a diagnostic utility of different inflammatory markers.
Results: Before antibiotic therapy all inflammatory markers including serum CPP (2821.1 ± 1072.4 pg/ml vs. 223.8 ±
109.3 pg/ml; p < 0.05) were higher in UTI than in controls. CPP was not different between L- and U-UTI (2253 ±
1323 pg/ml vs 3051 ± 1178 pg/ml; p = 0.70) despite significant differences in hsCRP (2.09 ± 1.7 mg/dl vs 127.3 ±
62.4 mg/dl; p < 0.001), PCT (0.05 ± 0 vs 5.02 ± 0.03 ng/ml p < 0.001) and IL-6 (22.5 ± 1.6 vs 84.8 ± 67 pg/ml p < 0.001).
For U-UTI the areas under the ROC curves were 1.0 for both hsCRP and CPP, 0.94 for PCT and 0.7 for IL-6 and for L-UTI
0.571, 1, 0.505 and 0.73, respectively. After 7 days of treatment all markers decreased in parallel to clinical response.
Conclusion: Although elevated serum copeptin may become a marker of UTI it seems to be inferior compared to
traditional serum inflammation markers for differentiation of bacterial infections involving upper and lower urinary tract.
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Background
Bacterial urinary tract infection (UTI) is the most com-
mon infection across all age groups. Although the part
of the urinary tract involved, i.e., low or upper UTI
needs to be quickly established this is not always
possible if based on clinical symptoms only. Typically,
clinical symptoms of lower (L-UTI) are dysuria, frequent
and difficult or painful urination. In most cases clinical
symptoms of upper UTI (U-UTI) are dominated by fever
and side pain [1]. In the latter an accurate diagnosis and
early treatment is crucial due to a risk of urosepsis and
long-term consequences including chronic kidney disease
[2, 3]. The duration of therapy recommended for L-UTI is
shorter compared to a complicated UTI that involves the
kidneys [4]. Thus there is a need to quickly and reliably
identify the biomarkers which could be used not only for
diagnostic purposes but also to determine the severity and
location of the infection inside the urinary tract.
Arginine vasopressin (AVP) is one of the key hormones
of cardio-vascular homeostasis and is an important part of
an endocrine stress response resulting in a release of
adrenal steroids [5]. Despite its dominant role in cardio-
vascular disease, the measurement and diagnostic appli-
cation of vasopressin have never been found useful in
clinical practice due to methodological problems caused
by its short half-life, functional interactions with platelets
in serum and small molecular size [6, 7].
Copeptin (CPP), is a 39-amino acid glycosylated peptide
[8]. Vasopressin and copeptin are derived from the same
precursor protein – pre-pro-vasopressin, composed of 164
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amino acids and consisting of single proteins: vasopres-
sin, neurophysin II and copeptin [9]. Thus, copeptin is
a C-terminal part of pro-vasopressin (CT-pro-AVP) and is
released along with vasopressin. In contrast to vasopres-
sin, copeptin is stable in serum or plasma in room
temperature and it is relatively easy to measure [10, 11].
Several recent studies have investigated the usefulness of
copeptin as a diagnostic and prognostic biomarker in
several clinical conditions including the lower respira-
tory tract infections [12], septic shock [13], and stroke
[14, 15]. To the best of our knowledge no study has sys-
tematically evaluated serum copeptin levels in both L-UTI
and U-UTI. The study was carried out in order to assess
the utility of a potential new serum inflammation marker
copeptin in diagnosis of UTI compared to other inflam-




The subjects for this single-center observational, prospect-
ive study were recruited from the patients manifesting
symptoms of UTI who were consecutively admitted to
our hospital from May 2011 through September 2012 and
diagnosed with acute pyelonephritis, as well as among
patients with symptoms of L-UTI who were treated in our
outpatient department. The reference group included
healthy subjects without any clinical and laboratory symp-
toms of infection. In all subjects from that group blood
was taken to confirm that blood count and C-reactive
protein level were within normal range. Also the urinalysis
was carried out to confirm an absence of leukocyturia.
The diagnosis of UTI in the subjects from the study
group was established on the basis of typical clinical
symptoms and at least one positive urine culture. The in-
clusion criteria included the presence of acute symptoms
like fever, flank pain (U-UTI) or pelvic pain (L-UTI),
dysuria, urinary frequency and costo-vertebral angle
tenderness (U-UTI), presence of pyuria. The exclusion
criteria included the eGFR <30 ml/min/1.73 m3, pres-
ence of any concomitant organ or systemic infection,
any hospitalization or surgical procedure within last
3 months, history of renal transplant and any perman-
ent complicating factors of urinary tract (including
complete obstruction, suspected or confirmed prosta-
titis) which cannot be effectively treated during the
therapy of the infection and ongoing or recent (within
last 7 days) antibiotic therapy. The patients with nega-
tive urine bacterial cultures and male subjects with
perineal or rectal pain and perineal tenderness during
the physical examination were excluded.
The Ethics Committee of the Medical University of
Lodz approved the study protocol. All the subjects pro-
vided a written informed consent.
Biochemical parameters
The following biochemical parameters were obtained
before commencing an antibiotic treatment and all
measurements were repeated according to the fixed
schedule after 24, 48 h and 7 days. They included
complete blood count, C-reactive protein (hsCRP), procal-
citonin (PCT), IL-6, serum sodium, potassium, creatinine
and serum copeptin. Urine and blood cultures were
assessed on admission and after seven days of antibiotic
therapy.
Circulating levels of copeptin were measured using a
commercial ELISA kit from USCN Life Science (Houston,
USA). All other parameters were measured with standard
laboratory automated methods.
Statistical analysis
All results are expressed as means ± SD and as median +/−
interquartile ratio (IQR). Data distribution was checked by
Kolmogorov – Smirnov test. Within-group comparisons
were performed using t-test or non-parametric Wilcoxon
test. For categorical variables, chi-square test or Fisher
exact test were used. The cutoff points of all markers to
optimum performance for differentiating L-UTI and U-
UTI were determined by plotting the Receiver Operating
Characteristic (ROC) curves [16]. Statistical analysis was
performed using Statistica for Windows (version 10PL,
StatSoft, Tulsa, OK, USA).
Results
No clinically relevant side effects prompting a change or
withdrawal of antibiotic therapy were observed.
Patients
The study group comprised 45 patients (31 female, 14
male, age 50 ± 20 years) including 13 with L-UTI (10
female, 3 male, age 61 ± 24 years) and 32 with U-UTI
(21 female, 11 male, age 54 ± 11 years). From 49 pa-
tients that were initially screened 4 were later excluded
because of negative urine cultures thus resulting in 45
patients taken into the final analysis. The reference
group included 24 healthy subjects (17 female, 7 male,
age mean 50 ± 20 years).
Biochemical parameters
Table 1 shows the clinical and biochemical characteris-
tics of the participants. Before the introduction of the
antibiotic therapy in UTI patients serum inflammation
markers such as: hsCRP (91.3 ± 86.5 mg/dl), PCT (3.7 ±
15.3 ng/ml) and IL-6 (66.8 ± 81.6 pg/ml) were all
significantly higher than in healthy patients (3.5 ±
2.3 mg/dl, 0.06 ± 0.02 ng/ml and 3.1 ± 1.6 pg/ml, re-
spectively, p < 0.05 for all comparisons. Serum copeptin
levels were also significantly higher in patients with
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UTI than in the controls (2821 ± 1072 vs. 223 ± 109 pg/
ml; p < 0.05).
There were significant differences in serum hsCRP,
PCT and IL-6 between L-UTI and U-UTI, but no
difference in serum copeptin was observed (Table 2).
Table 3 shows the comparison of biochemical parameters
assessed at the time of the admission to the hospital emer-
gency room in patients with the diagnosis of U-UTI.
Statistical significant differences of these parameters be-
tween study and reference group were observed. Table 4
shows the differences of serum inflammatory markers
between L-UTI and reference group. Only IL-6 and CPP
differed significantly between the groups.
On day 7 of antibiotic treatment, all serum markers
including serum copeptin levels, with the exception of
PCT, decreased significantly in patients with UTI along
with the clinical response (Table 5). Copeptin levels did
not completely return to normal range over the 7 days
of treatment (2821 ± 1072 pg/ml on day 0 vs. 2003 ±
838 on day 7, p = 0.0001).
Receiver operating curves (ROC) were plotted to assess
a diagnostic utility of inflammatory markers. As shown in
Table 6 the biomarkers that best identified U-UTI were
serum hsCRP and CPP followed by PCT and IL-6. In case
of L-UTI the best performing biomarker was serum CPP
followed by IL-6, hsCRP and PCT.
Discussion
To date several studies have been conducted to confirm
the hypothesis that copeptin, as a stress hormone, could
also be a biomarker of several pathologic conditions
including inflammation.
In our study a number of blood leucocytes, serum
hsCRP, PCT, IL-6 and CPP significantly increased in pa-
tients with UTI compared to healthy subjects. However,
trying to differentiate the patients with L-UTI from
those with pyelonephritis serum copeptin unlike other
inflammatory markers was not significantly different
between these groups.
The value of the assessment of serum copeptin and
other inflammatory markers in the diagnosis and differ-
entiating between U- from L-UTI was also established
by plotting the ROC curves. The area under the ROC
Table 1 Clinical and baseline biochemical characteristics of the
study group with urinary tract infection (UTI) and control group
UTI group Control P value
(n = 45) (n = 24)
Sex
Men 14 (31 %) 7 (29 %) NS
Women 31 (69 %) 17 (71 %)
Age (years) 56 ± 10 50 ± 20 NS
[64 (39)] [48.5 (33)]
Creatinine (mg/dl) 1.3 ± 0.3 1.0 ± 0.3 NS
[1.2 (0.4)] [1.0 (0.3)]
GFR (ml/min/1.73 m3) 73.1 ± 22 84.2 ± 26 NS
[72.6 (39.5)] [91.9 (41.6)]
Leucocyte count (G/l) 12.8 ± 6.7 6.4 ± 2.1 <0.001
[11.9 (6.9)] [5.6 (3.3)]
hsCRP (mg/L) 91.3 ± 86.5 3.5 ± 2.3 <0.001
[98.2 (132.5)] [3.3 (2.5)]
Procalcitonin (ng/ml) 3.7 ± 15.3 0.06 ± 0.02 <0.001
[0.12 (1.15)] [0.05 (0)]
IL −6 (pg/ml) 66.8 ± 81.6 3.1 ± 1.6 <0.001
[41.6 (92.3)] [2.8 (2)]
Copeptin (pg/ml) 2821 ± 1072 224 ± 109 <0.001
[874 (1527)] [209 (141)]
Results are expressed as mean ± SD [median (IQR)]
Table 2 Comparison of biochemical parameters assessed at
hospital admission in patients with diagnosis of lower and upper
urinary tract infection (UTI)
Lower UTI Upper UTI P value
(n = 13) (n = 32)
Leucocyte count (G/l) 8.6 ± 3.3 14.5 ± 5.9 0.005
[7.4 (3.4)] [12.7 (13.5)]
hsCRP (mg/L) 2.9 ± 1.7 127.3 ± 62.4 <0.001
[2.28 (2.81)] [132.5 (124.8)]
PCT (ng/ml) 0.05 ± 0 5.2 ± 0.03 <0.001
[0.05 (0)] [0.42 (0.9)]
IL −6 (pg/ml) 22.5 ± 1.6 84.8 ± 67 <0.001
[5.8 (41.9)] [57.9 (64.3)]
CPP (pg/ml) 2253 ± 1323 3051 ± 1178 Ns
[1757 (1403)] [2929 (2986)]
Results are expressed as mean ± SD [median (IQR)]
Table 3 Comparison of biochemical parameters assessed at
hospital admission in patients with diagnosis upper urinary tract
infection (U-UTI) and control group
Upper UTI Control P value
(n = 32) (n = 24)
Leucocyte count (G/l) 14.5 ± 5.9 6.43 ± 2.1 <0.001
[12.7 (13.5)] [5.6 (3.3)]
hsCRP (mg/L) 127.3 ± 62.4 3.5 ± 2.3 <0.001
[132.5 (124.8)] [3.3 (2.5)]
PCT (ng/ml) 5.2 ± 0.03 0.06 ± 0.02 <0.001
[0.42 (0.9)] [0.05 (0)]
IL −6 (pg/ml) 84.8 ± 67 3.1 ± 1.6 <0.001
[57.9 (64.3)] [2.8 (2)]
CPP (pg/ml) 3051 ± 1178 224 ± 109 <0.001
[2929 (2986)] [209 (141)]
Results are expressed as mean ± SD [median (IQR)]
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curve of copeptin was equal in lower and upper urinary
tract infection. It seems therefore that the measurement
of serum copeptin seems to less clinically useful than the
estimation of serum CRP and PCT to distinguish be-
tween L- and U-UTI.
Several earlier studies have investigated serum copep-
tin levels in different acute disorders. Serum copeptin
was significantly higher in patients with lower respira-
tory system infection in comparison to healthy persons,
with the highest level observed in patients with the
community acquired pneumonia [12]. The patients with
positive blood cultures had higher copeptin levels than
patients with negative blood cultures. All our patients
with UTI had positive urine cultures but negative blood
cultures that did not allow the direct comparison of our
results with the study of Muller et al. [12] that investi-
gated the patients with more severe systemic infections.
Morgenthaler et al. assessed serum copeptin levels in
patients with septic shock [13]. Increased copeptin was
observed at time of hospital admission, including pa-
tients with different severity of sepsis compared with
healthy control. Mean baseline serum copeptin was
higher in patients who survived sepsis in comparison to
those who died. Fluri at al. [14] performed the study
comparing inflammatory markers and copeptin levels
in patients suffering from stroke as early predictors for
the development of post-stroke infection [14]. Serum
procalcitonin, hsCRP, copeptin and leukocyte number
were assessed as well as markers of pneumonia, UTI
and other systemic infections. In that study mean levels
of copeptin, CRP and number of leukocytes in blood in
patients with UTI were similar to those with pneumo-
nia and other infections with the exception of procalci-
tonin level that was lower in the former. In the patients
with L-UTI in our study, increased levels of copeptin
and IL-6 were observed but no other serum markers
significantly differed from control group. That was not
the case in patient with pyelonephritis, in whom serum
levels of all markers were significantly higher compared
to controls. Fluri et al. [14] concluded that copeptin,
procalcitonin, CRP and number of blood leukocytes
were good serum inflammatory markers in pneumonia
and UTI however he did not divide their patients into
L- and U-UTI. They also postulated that a combination
of markers, including copeptin may be more helpful when
making the decision about introducing a prophylactic
antibiotic in patients with high risk of infection [14].
Copeptin levels were also measured in several studies
performed in non-infectious diseases. Rechlin and Muller
assessed the dynamic changes of copeptin levels in
myocardial infarction [15]. In patients with myocardial
infraction, copeptin levels increased within 4 h after the
first symptoms, while troponin T levels still remained
within normal range. Serum copeptin levels later
decreased while troponin remained increased for the
following several hours. The different kinetics of these
markers could be used in the diagnosis of myocardial
Table 4 Comparison of biochemical parameters assessed at
hospital admission in patients with diagnosis lower urinary tract
infection (L-UTI) and control group
Lower UTI Control P value
(n = 13) (n = 24)
Leucocyte count (G/l) 8.6 ± 3.3 6.43 ± 2.1 NS
[7.4 (3.4)] [5.6 (3.3)]
hsCRP (mg/L) 2.9 ± 1.7 3.5 ± 2.3 NS
[2.28 (2.81)] [3.3 (2.5)]
PCT (ng/ml) 0.05 ± 0 0.06 ± 0.02 NS
[0.05 (0)] [0.05 (0)]
IL −6 (pg/ml) 22.5 ± 1.6 3.1 ± 1.6 <0.001
[5.8 (41.9)] [2.8 (2)]
CPP (pg/ml) 2253 ± 1323 224 ± 109 <0.001
[1757 (1403)] [209 (141)]
Results are expressed as mean ± SD [median (IQR)]
Table 5 Leucocyte count, IL-6, CRP, PCT and CPP levels during the treatment of UTI
Day 0 Day 1 Day 2 Day 7 P value
Leucocyte count [G/l] 12.8 ± 6.7 10.5 ± 5.7 8.7 ± 3.9 6.6 ± 1.8 <0.001
[11.9 (6.9)] [8.9 (5.4)] [7.3 (4.5)] [6.7 (2.3)]
IL-6 [pg/ml] 66.8 ± 81.6 70.6 ± 98.7 49.3 ± 68.4 34.4 ± 64.8 <0.001
[41.6 (92.3)] [22.9 (90.5)] [12.6 (73.6)] [8.7 (29.9)]
hsCRP [mg/dl] 91.3 ± 86.5 77.6 ± 77.8 56.7 ± 72.7 13.5 ± 16.9 <0.001
[98.2 (132.5)] [57.6 (121.9)] [25.29 (84.12)] [7.4 (11.2)]
PCT [ng/ml] 3.7 ± 15.3 1.8 ± 8.2 1.1 ± 4.6 0.4 ± 1.7 0.11
[0.12 (1.15)] [0.08 (0.5)] [0.05 (0.2)] [0.05 (0.03)]
CPP [pg/ml] 2821 ± 1072 2309 ± 890 2290 ± 799 2003 ± 838 <0.001
[2874 (1527)] [2134 (934)] [2140 (891)] [1814 (1151)]
Results are expressed as mean ± SD [median (IQR)]
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infraction. In our study we only assessed the changes of
serum copeptin from the appearance of first symptoms
of urinary tract infections to the day 7 of antibiotic
treatment. Although high initial copeptin concentration
was observed its decrease was slower compared to
other inflammatory markers. Copeptin was still above
normal at day 7 while the concentration of other in-
flammatory markers approached normal values at that
time.
The potential biomarkers such as copeptin have to be
always estimated in the context of a careful clinical as-
sessment. Similar to many other biomarkers assessment
of copeptin has certain limitations. There are possibly
many factors which can lead to false – positive and
false – negative serum copeptin results [16]. For ex-
ample prednisone therapy increases copeptin concen-
tration compared to healthy persons [17]. That was not
the case in our patients since none was on steroids.
Serum copeptin levels are also higher in patients with
end-stage chronic kidney disease [18]. In our study
however the patients with advanced kidney disease
were excluded.
The use of new biochemical biomarkers that can sim-
plify diagnostic and prognostic evaluation is not always
economically feasible in particular since diagnostics
and prognostics are customarily based on several differ-
ent parameters. However, the usefulness of biomarkers
is defined by the degree of their impact on clinical deci-
sion making and by adding subsequent information,
apart from easily accessible data obtained from patients’
physical examination [19]. Although serum copeptin
could be a clinically useful inflammation marker in case
of UTI, our results show that it seems to be inferior
compared to traditional serum inflammation markers
for the differentiation of infections involving upper and
lower part of the urinary tract.
The main limitation of our exploratory research per-
formed in a single center was a relatively small group
of patients.
Conclusion
Although elevated serum copeptin may become a marker
of UTI it seems to be inferior compared to traditional
serum inflammation markers for differentiation of infec-
tions involving upper and lower urinary tract.
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